BridgeMD
Efficacy and safety of octreotide in laparoscopic hepatectomy surgery: effect on blood loss, need for vasoactive drugs, transfusion requirement.
EU CTIS ID: 2023-503613-29-00
What this study is testing
Observe the effects on intraoperative bleeding (measured in ml of blood lost) associated with the intraoperative administration of octreotide in laparoscopic hepatectomy surgery in relation to placebo.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients diagnosed with hepatic lesions who are going to undergo laparoscopic hepatectomy.
- The patient must be between 18 and 80 years old.
- The patient, or his/her representative, has given his/her consent to participate in the study.
- The patient must, in the opinion of the investigator, be able to comply with all the requirements of the clinical trial.
- The patient must not be allergic to the drug.
You likely can't join if
- History of hypersensitivity to the drug to be administered
- Children under 18 years of age.
- Urgent intervention.
- Intervention performed in an open manner (not laparoscopic).
- Patient's refusal to participate in the study.
- Contraindication to receive octreotide.
See the full eligibility criteria
- Patients diagnosed with hepatic lesions who are going to undergo laparoscopic hepatectomy.
- The patient must be between 18 and 80 years old.
- The patient, or his/her representative, has given his/her consent to participate in the study.
- The patient must, in the opinion of the investigator, be able to comply with all the requirements of the clinical trial.
- The patient must not be allergic to the drug.
- History of hypersensitivity to the drug to be administered
- Children under 18 years of age.
- Urgent intervention.
- Intervention performed in an open manner (not laparoscopic).
- Patient's refusal to participate in the study.
- Contraindication to receive octreotide.
- Women of childbearing age (those women who are in the period between menarche and menopause). Having to present a negative pregnancy test to take part in the study.
- Pregnant or lactating women given the absence of studies of this drug in this patient profile.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.